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Edited by Jesus AvilaAbstract Parkinson’s disease (PD) is a slow progressive
neurodegenerative disorder. Recent evidence suggests a central
role for a-synuclein, a protein of unknown function, in the genesis
of PD. The phenomenon of selective degeneration of dopami-
nergic neurons in PD may be linked to the potential toxicity of
dopamine itself and aberrations in the processes which regulate
dopamine content may underlie the pathogenesis of this disease.
Here, we review a vital role of a-synuclein in the modulation of
dopamine transporter (DAT) function, and describe how disrup-
tion of this modulatory process permits increased re-uptake of
high levels of intracellular dopamine by DAT, causing profound
neurotoxicity.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Parkinson’s disease (PD) is a neurodegenerative disease,
primarily aﬀecting the elderly, characterized by a progressive
impairment of automatic aspects of behaviors, namely sen-
sory neglect, hypokinesia and rigidity. The pathological
hallmarks of PD are a striking loss of dopamine-producing
neurons in the substantia nigra (SN), causing dopamine de-
pletion in the striatum, on the one hand, and the presence of
neuronal cytoplasmic inclusions known as Lewy bodies
(LBs), on the other hand [1]. Although oxidative stress and
mitochondrial dysfunction have been implicated in the dis-
ease process, the mechanisms underlying the selective death
of nigral neurons in PD are still unknown. Most cases of PD
are sporadic, but rare, familial forms of the disease do exist.
To date, early-onset PD has been linked to mutations in four* Corresponding author. Fax: +1-202-687-0279.
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oxygen species; NAC, non-amyloid component; CT, carboxy-terminal
tail; MPPþ, 1-methyl-4-phenylpyridinium; VMAT2, vesicular mono-
amine transporter
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doi:10.1016/j.febslet.2004.03.063genes, a-synuclein, parkin, UCH-L1 and DJ1 [2–4]. Autoso-
mal dominant forms of the disease result from mutations in
a-synuclein leading to Alanine30–Proline [A30P] and Ala-
nine53–Threonine [A53T] substitutions [5,6]. Even though
these mutations are not present in the majority of patients
with familial PD [7], and not found in idiopathic PD [8],
numerous studies showed the selective accumulation of a-
synuclein in LBs [9,10], suggesting a central role for wild type
(wt) a-synuclein in mediating dopamine (DA) neuronal death
[11–14].
In this review, we will present evidence to show that one of
the normal functions of a-synuclein is the modulation of
dopamine transporter (DAT) function, regulating the synap-
tic tone of dopamine. Disruption of this function of a-syn-
uclein can result in abnormal intracellular and extracellular
dopamine content, which can ultimately lead to neurode-
generation of the nerve terminals. Moreover, through its
regulation of the DAT, we present evidence to support our
hypothesis of a contribution of a-synuclein to the highly se-
lective degeneration of dopamine-producing, DAT expressing
neurons seen in PD.2. a-Synuclein
a-Synuclein, a 140-amino acid protein of 19 kDa
[11,15,16], was originally isolated from cholinergic vesicle
preparations of the electric organ of the ray Torpedo califor-
nica [17], and later from amyloid plaques of Alzheimer’s dis-
ease brains [18,19]. a-Synuclein belongs to a multi-gene family
encoding structurally closely related proteins that are abun-
dantly expressed in presynaptic terminals of various brain re-
gions and include the a-, b- and c-synucleins [12,15,16].
a-Synuclein exists either as a poorly structured protein in
aqueous medium or as an a-helix-shaped protein, when asso-
ciated to phospholipids or cellular membranes. The function of
a-synuclein is still unknown, although several studies suggest
that it plays an important role in synapse maturation and
maintenance [15,16,20]. Its expression is developmentally reg-
ulated, redistributing from neuronal cell bodies to synaptic
terminals during periods of neuronal diﬀerentiation [15,21] and
it is up-regulated during periods of synaptic plasticity [22].
Depletion of a-synuclein in neurons is associated with
decreased production of synaptic vesicles, probably through itsation of European Biochemical Societies.
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phospholipid pathway ([20], and references therein).
How a-synuclein may be implicated in the pathophysiologi-
cal process of PD is far from obvious, but a prerequisite of a-
synuclein neuropathy is its oligomerization into soluble pro-
toﬁbrils [23,24] followed by their coalescence into insoluble ﬁ-
brils [10,24], composed of b-sheets and amyloid-like ﬁlaments
[25,26], prior to their aggregation into insoluble ﬁbrillar
structures and inclusions, which then accumulate into LBs [14].
Several experimental conditions, including overexpression of
the protein, presence of the A30P or A53T mutations, exposure
to neurotoxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydro-
pyrimidine (MPTP) or rotenone, and oxidative factors, induce
or accelerate a-synuclein aggregation, through procedures that
remain poorly understood [13,14,26–28]. Once aggregation is
initiated, the bioavailability of a-synuclein is substantially di-
minished such that normal physiological functions regulated by
this protein may be severely compromised, which in turn, could
further exacerbate the initial cellular insult.
A puzzling aspect of a-synuclein-mediated cytotoxicity and
LBs formation with regard to PD is the preferential and
selective neurodegeneration of dopamine-producing neurons ofFig. 1. The dopaminergic nerve terminals and the components that
regulate dopamine metabolism at the nerve terminals. Synthesized DA
(red) is accumulated and stored inside synaptic vesicles through the
vesicular transporter VMAT2 (blue pentagons). After exocytotic re-
lease into the extracellular space, dopamine is fastly taken up by the
plasma membrane DAT (violet hexagons), and then enzymatically
degraded by monooxidase B (MAOB, green). The intracellular amount
of free dopamine thus depends on the amount of DAT at the plasma
membrane and on the availability of VMAT2 on synaptic vesicles. As
soon as the amount of free dopamine increases inside the nerve ter-
minals, oxidized dopamine and ROS (yellow) are produced and may
be deleterious to the cells. The DAT shuttles between the plasma
membrane and intracellular compartments, DAT endocytosis being
favored by speciﬁc phosphorylation of the transporter and by the
presence of a-synuclein. In normal situation, this latter exists either in
soluble form or in membrane-bound form. Formation of protoﬁbrils,
upon either speciﬁc mutations (mainly A53T) or oxidative stress, tends
to decrease the amount of soluble a-synuclein, to increase the amount
of DAT at the plasma membrane and the amount of free dopamine in
the neurons, triggering a vicious cycle of cellular stress.the SN, particularly since it is ubiquitously expressed at high
levels in virtually all brain regions, accounting for up to 0.1% of
total brain protein [11,12]. Increasingly, the evidence suggests
that the speciﬁc vulnerability of these neurons is linked to the
cytotoxic potential of dopamine itself, mediated both through
its auto-oxidation catalyzed by free transition metals (mostly
free Fe2þ) [29] and its enzymatic deamination by monoamine
oxidases to yield toxic DA metabolites and reactive oxygen
species (ROS), such as superoxide and hydroxyl radicals [30]
(Fig. 1). Thus, a failure to properly regulate the intracellular
content of DA may cause abnormally high cytosolic levels of
DA, leading to generation of cytotoxic DA metabolites and
ROS, which in turn can promote oxidative stress, terminal
degeneration, and eventually neuronal death [20].3. a-Synuclein and its A30P mutant modulate the functional
activity of the dopamine transporter
Oneof themain consequences of the presence ofa-synuclein at
the nerve terminals of dopamine-synthesizing neurons is its ef-
fects on the regulation of the plasma membrane DAT. As a-
synuclein, the DAT is expressed in presynaptic terminals of SN
dopaminergic neurons where it mediates the re-uptake of syn-
aptically released dopamine ([31–33] and references therein) The
importance of DAT function in the control of synaptic avail-
ability of dopamine suggests that its own regulation may be a
crucial component in the maintenance of dopaminergic neuro-
transmission, and thereby in the levels of intracellular dopamine,
since enhanced DAT activity would increase intracellular levels
of dopamine, resulting in excessive ROS production within do-
paminergic neurons (Fig. 1). DAT function is mostly regulated
through its rapid shuttling to and from the plasma membrane
[32]. A rapid redistribution and internalization of DAT occurs
after its phosphorylation by various kinases [34–36], suggesting
rapid adaptation of the neuron, in response to signal transduc-
tion-induced changes, to modulate DAT function.
We have recently shown that upon co-expression in Ltk
ﬁbroblasts, or in basal conditions in mesencephalic neurons,
wt a-synuclein tends to markedly decrease (by 30–50%) DAT-
mediated uptake of extracellular dopamine [37,38], at amounts
of the two proteins that mimic the endogenous situation seen
in normal rat SN [39]. The reduction in DAT activity was due
to decrease in dopamine uptake velocity, without any changes
in aﬃnity or DAT expression levels. As a consequence, do-
pamine-induced oxidative stress and cytotoxicity were de-
creased in cells co-expressing DAT and wt a-synuclein. In the
presence of wt a-synuclein, DAT was dynamically traﬃcked
away from the plasma membrane into the cytoplasm, as in-
dexed by reduced DAT presence at the plasma membrane by
biotinylation experiments [38,40] (Fig. 1). From co-immuno-
precipitation studies, a-synuclein was found to interact directly
with the DAT, forming a protein:protein heteromeric complex
in transfected cells, primary cultures of mesencephalic neurons
and rat SN [37,38,41]. These interactions occurred between the
non-amyloid component (NAC) domain (residues 58–107) of
wt a-synuclein and the last 22 amino acids of the carboxy-
terminal (CT) tail of DAT [38].
Similar to the wt a-synuclein, the A30P mutant also attenu-
ated DAT function, traﬃcking DAT away from the plasma
membrane and participating in the formation of protein:
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58–107) of A30P and the last 22 amino acids of the CT tail of
DAT [42]. Interestingly, the A53T mutant was unable to mod-
ulate DAT function and subsequent studies showed that this
protein only very weakly interacted with the transporter [42].
Recent evidence from our laboratories suggests that cell
adhesion may play a role in dictating the functional outcome
of DAT/a-synuclein interactions. Thus, batch-transfection of
co-transfected cells followed by cell detachment and reseeding
using trypsin, resulted in the opposite eﬀect of wt a-synuclein
on DAT, i.e., an increase of DAT activity [38], in agreement
with Lee et al. [41]. Moreover, mild trypsinization of co-
transfected cells or of neurons, under conditions which do not
cause a signiﬁcant cell dissociation, reversed the attenuation of
DAT function by a-synuclein [40] (Fig. 2). This eﬀect of
trypsin was mimicked by other proteases used to dissociate
cells, such as collagenase or dispase, but not by proteases
which do not signiﬁcantly aﬀect cell adhesion, such as chy-
motrypsin, pronase or papain [40]. Impaired cell adhesion did
not disrupt the physical interactions between wt a-synuclein
and DAT, but promoted a pronounced redistribution of the
DAT, which is recruited at the plasma membrane [40] (Fig. 2),
indicating that a-synuclein may act to tether the DAT to a
cytoplasmic compartment, thereby keeping it away from the
cell surface (Fig. 2). Similar eﬀects were also seen with the
A30P mutant, but not with the A53T variant.
Most interesting, however, was the ﬁnding that the parkin-
sonian syndrome-inducing agent, 1-methyl-4-phenylpyridi-
nium ion (MPPþ), whose intracellular transport within neurons
occurs speciﬁcally only through the DAT, also reversed theFig. 2. The regulation of dopamine uptake in normal (left) and impaired (right
presence of suﬃcient amounts of soluble a-synuclein tends to decrease the am
free dopamine enter the terminals, which are eﬃciently accumulated in syn
cytoskeleton integrity is impaired (or both, right part of the ﬁgure), a-synuc
which thus goes preferentially to the plasma membrane. Similarly, a-synuclein
synuclein and triggers DAT recruitment to the plasma membrane. In this con
form oxidized and reactive species. DAT is also the mean used by the mitocho
of reactive, highly toxic oxygen species. Since oxidative stress strikingly favor
of DAT at the plasma membrane, a very eﬃcient cascade of events takes plac
presence of a-synuclein and DAT in dopaminergic nerve terminals is a key-
pamine neurons in PD.inhibitory eﬀects of wt a-synuclein on DAT [38]. Under all
experimental conditions, where the dopamine transporter
activity was dysregulated, there was increased re-uptake of
dopamine and dopamine-induced neurotoxicity, suggesting
that disruption of the ability of wt a-synuclein to regulate DAT
function may be one of the most important determinants in the
genesis of dopaminergic neurodegeneration (Fig. 2).4. a-Synuclein and its A53T mutant modulate the amount of the
vesicular transporter vesicular monoamine transporter in
dopamine nerve terminals
A striking aspect of our studies is the absence of any mod-
ulation by the A53T mutant of a-synuclein on DAT function.
However, recent studies [20,43] suggest that the A53T mutant
can modulate the vesicular monoamine transporter (VMAT2)
[44]. In MESC2.10 human mesencephalic cells the presence of
the A53T mutant decreased expression of VMAT2, accom-
panied by decreased potassium-induced, and increased am-
phetamine-induced, dopamine release [43]. The consequence of
such increased levels of cytosolic dopamine was enhanced su-
peroxide production and cytotoxicity [43]. These results sug-
gest that the A53T mutant, through its eﬀects on VMAT2,
causes an impairment in vesicular dopamine storage and re-
lease. Although the mechanisms of a-synuclein depletion of
VMAT2 are not known, it is probable that the decrease in the
number of synaptic vesicles that accompanies impaired a-
synuclein functions plays a role in this decreased amount of
VMAT2 at the synapses.) nerve terminals. In healthy nerve terminals (left part of the ﬁgure), the
ount of DAT at the plasma membrane. Thus, reasonable amounts of
aptic vesicles through VMAT2 activity. As soon as cell adhesion or
lein is no longer able to favor the intracellular accumulation of DAT,
aggregation in ﬁbrils or LBs tends to decrease the amount of soluble a-
dition, dopamine is able to enter massively into nerve terminals and to
ndrial poison MPPþ to enter into neurons, triggering huge production
s a-synuclein aggregation and thus favors the presence of high amounts
e to trigger neuronal toxicity and degeneration. Clearly, the combined
element to understand the speciﬁc degeneration of mesencephalic do-
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variants of a-synuclein can regulate the function of the two key
proteins that control the amount of dopamine inside nerve
terminals, DAT and VMAT2. Thus, the wt a-synuclein and its
A30P mutant can regulate the DAT, thereby controlling the
extravesicular cytoplasmic levels of dopamine, while the A53T
mutant regulates VMAT2, controlling the vesicular uptake of
dopamine. Aberrations in any of these systems could cause
increases in free cytoplasmic dopamine, which upon autoxi-
dation and enzymatic metabolization can generate ROS, ulti-
mately leading to neuronal death.5. Dopamine-linked aberrations convert a-synuclein into a toxic
molecule
In a normal situation, a-synuclein exists as a soluble or lipid-
bound structure. In pathological states, a-synuclein can form
protoﬁbrils, reducing the bioavailability of the physiological
form of the protein [24], and increasing the toxic potential of
dopamine at nerves terminals (Fig. 2). Free radicals such as
free iron or iron-centered radicals [29] and oxidized dopamine
and catecholamines structurally related to dopamine [23], ac-
celerate and stabilize the formation of a-synuclein protoﬁbrils
by inhibiting the conversion of toxic soluble protoﬁbrils into
insoluble ﬁbrils. The formation of a-synuclein protoﬁbrils is
also facilitated by high levels of a-synuclein in vitro [27] and in
transgenic Drosophila [45], or by the presence of the A53T
mutation in mice [46]. Thus, it is clear that impaired storage of
dopamine into synaptic vesicles, or dysregulation of DAT, will
increase the levels of free intracellular dopamine, triggering a
vicious circle of events, leading to aggregation of a-synuclein,
thereby signiﬁcantly contributing to the rather speciﬁc degen-
eration of the dopamine-synthesizing neurons of the mesen-
cephalon in human PD. The lower amount of a-synuclein
immunoreactivity observed by us in the SN, compared to other
brain areas, suggests that nigral dopaminergic neurons may be
particularly vulnerable to a pathological increase in a-synuc-
lein protein levels [39].
Studies linking MPPþ and a-synuclein eﬀects further high-
light the central role of the determinants of dopaminergic
systems in the induction of the processes leading to a-synuclein
toxicity (Fig. 2). Here, the expression of DAT confers the
selectivity of MPPþ toward SN [47], since this neurotoxin
enters the dopaminergic neuron through DAT in an energy-
dependent manner. Once in the cell, MPPþ inhibits complex I
of the mitochondrial respiratory chain, releasing cytochrome c,
which accelerates aggregation of a-synuclein [48], ultimately
aﬀecting the properties of a-synuclein (Fig. 2). The presence of
a-synuclein and its A53T mutant enhances the vulnerability of
cells to MPPþ exposure [49], whereas a-synuclein null-mice are
essentially resistant to MPTP-induced degeneration of dopa-
minergic neurons [50]. This further suggests that a-synuclein
has a facilitatory role in enhancing, either directly or indirectly,
the observed toxicity of MPPþ.6. Conclusion
To conclude, there is ample evidence to propose that overall,
a-synuclein itself is not a toxic protein, but it can be convertedto a toxic molecule in the presence of oxidized dopamine. In
addition, a-synuclein regulates the major factors that regulate
amounts of free dopamine in the dopaminergic neurons, DAT
and VMAT2, thereby conferring the selectivity for degenera-
tion of dopamine-producing neurons seen in PD. This hy-
pothesis certainly does not recapitulate all the possible
mechanisms envisaged to exist at the onset of PD, but it has
the merit to include other well-demonstrated components of
PD etiology, including genetic components and neurotoxins,
which may all enter, at multiple entry points, into the delete-
rious cycle of a-synuclein protein aggregation and ROS pro-
duction. Considering that DAT, VMAT2 and a-synuclein as
key players in the chain of events leading to PD pave the way
for therapeutic interventions, while providing a more accurate
understanding of both the physiology and the pathology of
dopamine neurotransmission.
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